Contact Search
Contact us
Have questions or need assistance? We're here to help! Whether you’re looking for legal advice, business solutions, or general inquiries, we're happy to assist you.

Phone Number:
+41 58 261 50 00

Email:
Turn on Javascript!

Mailing Address:
Brandschenkestrasse 90
8002 Zurich
Switzerland

Further Office Addresses
Contact us
Have questions or need assistance? We're here to help! Fill out the form below, and our team will get back to you as soon as possible. Whether you’re looking for legal advice, business solutions, or general inquiries, we're happy to assist you.
By submitting the form, I confirm that I have noted and accepted the legal notes and the terms of use and that I have acknowledged the privacy statement.
13 August 2018 | Deals & Cases

Nadja Jaisli Kull Acted as Sole
Arbitrator in a DIS Arbitration
Regarding the World-Wide Distribution of
a Medical Device

13 August 2018 | Deals & Cases
Nadja Jaisli Kull Acted as Sole
Arbitrator in a DIS Arbitration
Regarding the World-Wide Distribution of
a Medical Device
In a DIS arbitration brought by a German producer against US and German distributors regarding the world-wide distribution of a medical device, Nadja Jaisli Kull acted as Sole Arbitrator.
Tags
Healthcare & Life Sciences
Arbitration
Team involved
Partner
Nadja Jaisli Kull

Further Deals, Cases & News

Corporate News - 26 March 2026
Bär & Karrer Recognised in 13 Tier 1 Rankings and 35 Individual Rankings by The...
Bär & Karrer reaffirms its position as one of Switzerland’s leading law firms with top-tier recognition from Legal 500 across 13 key practice areas....
Read More
Corporate News - 19 March 2026
Bär & Karrer Receives Band 1 Recognition in Seven Key Practice Areas from...
Chambers Europe has released its 2026 rankings and Bär & Karrer has once again secured Band 1 recognition for our performance and expertise in...
Read More
Deals & Cases - 12 January 2026
Nxera Pharma concludes License Agreement with and invests into Santhera...
Nxera Pharma Co. Ltd, listed on the Tokio Stock Exchange, has entered into an exclusive licensing agreement with Santhera Pharmaceuticals under which...
Read More
More Deals, Cases & News